March 18, 2015. Developer of a cell programming platform intended to make biology easier to engineer. Ginkgo Bioworks uses advanced biotechnology to grow various consumer products rather than manufacturing them, enabling fragrance, cosmetic, nutrition ��� Ginkgo Bioworks's main competitors include LGC, Principia BioPharma, Verona Pharma and Vectura Group. Ginkgo Bioworks is the organism company, using the power of biology to build sustainable products in food, pharma, manufacturing, and more. Ginkgo Bioworks is an analytics company that designs organisms for customers in a range of industries. Price per share is $150,19. Ginkgo���s Investment is Key for Synlogic. At Ginkgo, we see the potential for biology to transform all industries. Data & News supplied by Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. BOSTON, Oct. 26, 2020 /PRNewswire/ -- Today, Ginkgo Bioworks announced it has secured access to the SD Biosensor rapid antigen test with a goal of acquiring and distributing up to 50 million tests. It also provides probiotic bacteria to protect the body from dangerous infections and generates libraries of ��� It seems that the deal has excited investors as Cronos stock was up 13% on the news.. Ginkgo Bioworks Signs Deal with Cronos to ��� Ginkgo Bioworks has inked a $122 million USD deal with Toronto's Cronos Group (TSX:CRON). Ginkgo Bioworks General Information Description. Cronos Group stock jumps after partnering with Boston biotech Ginkgo Bioworks in a US$122mln deal to develop cultured cannabinoids. Press Release Ginkgo Bioworks CEO to Present at the 39th Annual J.P. Morgan Healthcare Conference Published: Jan. 8, 2021 at 1:44 p.m. Ginko Bioworks recently closed a $9M Series A from investors including Vast Ventures, Data Collective, and Felicis Ventures (link). Passive Investment. Tags Ginkgo Bioworks TC boston. Ginkgo Bioworks is a company that designs, engineers, develops, tests, and licenses organisms. It is the self-proclaimed "Organism Company" and is one of the ��� Ginkgo Bioworks��� revenue comes from two channels. Ginkgo Bioworks Lands $9 Million In Series A Funding To Build Out New Lab Facilities. As one of the leading biopharmaceutical companies, Synlogic Inc (SYBX) makes use of synthetic biology to genetically engineer living medicines. Concentric by Ginkgo, the company's COVID-19 diagnostic testing service, will begin offering antigen testing to customers in international markets where the antigen test is authorized to ��� Tickers TC. Compare Ginkgo Bioworks to its competitors by revenue, employee growth and other metrics at ��� Ginkgo Bioworks is an American biotech company founded in 2009 by scientists from MIT and headed by Tom Knight.The company specializes in using genetic engineering to produce bacteria with industrial applications. Working with our partners and growing ecosystem, we design custom organisms that bring new products to life for countless applications. After Forbes unveiled its annual billion-dollar startup list on Sept. 26, 2017, some anxious investors started targeting the SYBX stock is making solid movement after Synlogic Inc (NASDAQ:SYBX) announced an $80 million equity investment from Ginkgo Bioworks. MIRN / Mirna Therapeutics, Inc. / Ginkgo Bioworks, Inc. - SCHEDULE 13G FOR SYNLOGIC, INC. BY GINKGO BIOWORKS, INC. Ginkgo Bioworks has secured a total of $790 million from venture investors. )* Synlogic, Inc. (Name of Issuer) Common Stock, ��� From TechCrunch. It discovers molecules in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. The Organism CompanyWe���re building the backend of the bioeconomy.Biology is everywhere. Featured Work:Growing Ginkgo���s Platform with Digital TechnologyJoyn BioStrain ��� BOSTON, Dec. 23, 2020 /PRNewswire/ -- Today Ginkgo Bioworks, the organism company, announced the launch of its pilot program to bring COVID-19 pool ed testing to K-12 classrooms. 2019-06-21 - 1 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. The biotech will genetically engineer cannabinoids so that Cronos can bring cannabinoid-based products to market with reliability and scalability . U.S. Loans $1.1 Billion to Ginkgo Bioworks for Pandemic Effort By Reuters , Wire Service Content Nov. 25, 2020 By Reuters , Wire Service Content Nov. 25, 2020, at 8:08 a.m. BOSTON, Nov. 25, 2020 /PRNewswire/ -- Ginkgo Bioworks announced today that the U.S. International Development Finance Corporation (DFC) has approved a loan of up to $1.1 billion, enabling Ginkgo to expand ongoing biosecurity efforts.These include optimizing the manufacturing of COVID-19 vaccines, delivering widespread testing, and building the infrastructure needed to help ��� Ginkgo Bioworks, the organism company, today announced it is contributing its platform infrastructure and expertise to a project with Moderna, Inc. (Nasdaq: MRNA). BOSTON, Nov. 20, 2020 /PRNewswire/ -- Today, Ginkgo Bioworks announced it has secured access to at least 10 million rapid antigen test kits from Access Bio, ��� Ginkgo Bioworks is a startup that turns bacteria into consumer goods, and the partnership will allow the company to apply its technology to cannabis.. Ginkgo Bioworks is the organism company, using the power of biology to build sustainable products in food, pharma, manufacturing, and more. Now Ginkgo shares on the OTC market are worth $138.6, which suggests a valuation of $4 billion. ET By accessing this page, you agree to the following Its last funding in September 2019 valued the company at $4.4 billion. Ginkgo Bioworks ("Ginkgo"), the organism company, today announced that it has recently completed an acquisition of the main assets of Novogy, Inc. ("Novogy").